Regeneron Pharmaceutical (REGN) 431.24 $REGN Sanofi and

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Regeneron Pharmaceutical (REGN) 431.24 $REGN

Sanofi and Regeneron Announce EMA Acceptance for Review of Marketing Authorisation Application for Sarilumab
PR Newswire Europe - Mon Aug 01, 1:01AM CDT
GUILDFORD, England, August 1, 2016 /PRNewswire/ --
REGN: 431.24 (+6.12)

Regeneron Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.62%
Comtex SmarTrend(R) - Wed Jul 27, 12:53PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $399.00 to a high of $410.28. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $398.65 on volume of 443,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 431.24 (+6.12)

Regeneron Announces Upcoming 2016 Investor Conference Presentation
PR Newswire - Mon Jul 18, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the following investor conference:
REGN: 431.24 (+6.12)

Pfizer Publishes Final Data from Atopic Dermatitis Studies
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 11:10AM CDT
Pfizer (PFE) announced findings from two pivotal phase III studies on crisaborole for the treatment of patients with mild-to-moderate atopic dermatitis.
GWPH: 95.26 (+0.94), PFE: 37.03 (+0.14), SNY: 42.37 (-0.26), REGN: 431.24 (+6.12)

Amgen's Repatha Gains FDA Approval for New Dosing Option
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 9:20AM CDT
Amgen's (AMGN) PCSK9 inhibitor Repatha becomes the first and the only one to gain FDA approval for a monthly single-dose administration.
INVA: 13.27 (+0.40), AMGN: 173.97 (+1.94), SNY: 42.37 (-0.26), REGN: 431.24 (+6.12)

Regeneron to Report Second Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on August 4, 2016
PR Newswire - Fri Jul 08, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2016 financial and operating results on Thursday, August 4, 2016, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
REGN: 431.24 (+6.12)

Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 64.00 (+0.01), BIIB: 305.25 (+15.32), VRTX: 97.58 (+0.58), GILD: 79.72 (+0.25), UNH: 143.59 (+0.39), MRK: 58.66 (unch), ALXN: 131.43 (+2.83), XOM: 87.27 (-1.68), CVX: 101.22 (-1.26), REGN: 431.24 (+6.12), CELG: 114.63 (+2.44)

Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:09AM CDT
Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.
INVA: 13.27 (+0.40), PFE: 37.03 (+0.14), SNY: 42.37 (-0.26), REGN: 431.24 (+6.12)

Look for Shares of Regeneron Pharmaceuticals to Potentially Pullback after Yesterday's 2.49% Rise
Comtex SmarTrend(R) - Wed Jul 06, 12:24PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $355.61 to a high of $369.70. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $363.18 on volume of 477,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 431.24 (+6.12)

Company News for June 23, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 9:10AM CDT
Companies in the News are: TSLA,SCTY,FDX,ADBE,REGN
FDX: 162.04 (+0.14), TSLA: 231.11 (-3.68), SCTY: 25.37 (-1.33), REGN: 431.24 (+6.12), ADBE: 97.57 (-0.29)

How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 97.58 (+0.58), XON: 25.71 (+0.38), ARNA: 1.68 (+0.01), REGN: 431.24 (+6.12)

SmarTrend Watching for Potential Rebound in Shares of Regeneron Pharmaceuticals After 1.02% Loss
Comtex SmarTrend(R) - Mon Jun 13, 12:43PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $367.45 to a high of $375.38. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $369.60 on volume of 388,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 431.24 (+6.12)

The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 305.25 (+15.32), BMRN: 99.77 (+0.35), ALXN: 131.43 (+2.83), IBB: 293.73 (+4.29), REGN: 431.24 (+6.12)

4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 305.25 (+15.32), BMRN: 99.77 (+0.35), SRPT: 25.27 (-0.01), ALXN: 131.43 (+2.83), IBB: 293.73 (+4.29), REGN: 431.24 (+6.12)

Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 305.25 (+15.32), SRPT: 25.27 (-0.01), ALXN: 131.43 (+2.83), AMGN: 173.97 (+1.94), ABBV: 66.84 (+0.61), REGN: 431.24 (+6.12), CELG: 114.63 (+2.44)

Regeneron Pharmaceuticals Falls 1.47% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Jun 08, 12:24PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $383.98 to a high of $394.80. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $393.21 on volume of 473,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 431.24 (+6.12)

Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 305.25 (+15.32), VRTX: 97.58 (+0.58), PXD: 158.03 (-4.54), ALXN: 131.43 (+2.83), HAL: 42.65 (-1.01), EOG: 80.37 (-1.33), AMGN: 173.97 (+1.94), ILMN: 168.27 (+1.92), XOM: 87.27 (-1.68), COP: 39.93 (-0.89), JUNO: 31.10 (+0.17), CVX: 101.22 (-1.26), OXY: 74.16 (-0.57), REGN: 431.24 (+6.12)

Regeneron, Sanofi Report Positive Dupilumab Phase III Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:52AM CDT
Regeneron (REGN) and Sanofi reported that a phase III study on dupilumab in moderate-to-severe atopic dermatitis patients met the primary and secondary endpoints.
ANIP: 60.00 (-0.60), BMY: 75.39 (+0.58), SNY: 42.37 (-0.26), REGN: 431.24 (+6.12)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 264

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 317

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 367

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 414

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 217

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 238

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 121

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Van Horn Automotive Group Partners for Successful Dealership Sale

Updated Category News Views 928

Van Horn Automotive Group Sells Ford and Chevrolet Dealerships Performance Brokerage Services, recognized as a leader in dealership buy-sell transactions, has announced the acquisition of Van Horn Ford and Van Horn Chevrolet from Van Horn Automotive Group, marking an important transition for the dealerships. The new owners, Yelena and Alex Tovstanovsky of Sky Auto Mall,...

Continue Reading
G2 Goldfields Unveils Exciting Drilling Results at OKO

Updated Category News Views 136

G2 Goldfields Expands Mineral Resources at OKO G2 Goldfields Inc. (“G2”) (TSX: GTWO; OTCQX: GUYGF) has some exciting updates to share about its exploration activities at the vast 27,719-acre OKO-AREMU gold project. The company recently provided a significant update on their Mineral Resource Estimate (MRE), which now shows a remarkable total of 922,000 ounces of gold...

Continue Reading
Ecolectro Secures $10.5M Series A Funding for Green Hydrogen

Updated Category News Views 425

Ecolectro's Game-Changing Series A Funding Round Ecolectro has successfully completed a significant funding round, securing $10.5 million to enhance its innovative green hydrogen technology. The funding, led by Toyota Ventures, will enable Ecolectro to further develop its fully integrated and scalable electrolyzers, crucial for producing green hydrogen efficiently and...

Continue Reading
CEI Vision Partners Faces Data Breach Investigation: What to Know

Updated Category News Views 233

CEI Vision Partners Confronts Serious Data Breach Investigation In recent news, CEI Vision Partners, a prominent network of over 300 ophthalmologists and 700 optometrists, finds itself at the center of a significant data breach investigation. The investigation, led by the firm Schubert Jonckheer & Kolbe LLP, aims to uncover the details surrounding unauthorized access to...

Continue Reading
New Ethical AI Tools and Books Revolutionizing College Essays

Updated Category News Views 272

Innovative Solutions for College Essay Writing In light of recent prohibitions against artificial intelligence writing tools at major universities, students are navigating the challenges of crafting their college essays with greater scrutiny. College Essay Advisors has responded to this shift by introducing College EssAI, an innovative ethical AI platform designed to...

Continue Reading